Sunday, October 11, 2026

health-technology

5 articles

Canadian AI Heart Diagnostics Firm Risks Capital Wipeout as Cboe Listing Hangs in Balance

Canadian AI Heart Diagnostics Firm Risks Capital Wipeout as Cboe Listing Hangs in Balance

GuideAI Health Corp.'s conditional Cboe Canada listing could force a full return of investor proceeds if exchange requirements go unmet. The company is building AI diagnostics for cardiovascular disease — the world's leading killer — at a moment when clinical AI firms globally face high barriers to public capital. A failed listing would unwind its entire post-combination structure.

LM Salvado•
U.S. Radiology Giant Posts 36% EBITDA Jump, Offering AI Benchmark for Global Health Systems

U.S. Radiology Giant Posts 36% EBITDA Jump, Offering AI Benchmark for Global Health Systems

RadNet's adjusted EBITDA rose 36.3% year-over-year in Q1 2026, well ahead of its 22.1% revenue growth, driven by AI scheduling and diagnostic tools across its U.S. network. Advanced imaging volumes surged, with PET/CT up 35.2% and MRI same-center volume up 10.1%. The margin expansion offers a concrete financial reference point for hospital systems worldwide evaluating AI investment in radiology.

LM Salvado•
Intuitive Surgical's da Vinci 5 Clears Europe and Japan, Opening $2.3B Market as Q4 Beats Forecast

Intuitive Surgical's da Vinci 5 Clears Europe and Japan, Opening $2.3B Market as Q4 Beats Forecast

Intuitive Surgical secured regulatory approvals for its da Vinci 5 robotic system in Europe and Japan, unlocking markets worth $2.3 billion in annual surgical robotics spending. The company beat Q4 earnings forecasts while installing 415 systems globally, a 22% increase year-over-year. Force feedback and AI-powered features distinguish the new platform as competition intensifies across international markets.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com